Nosa Plugs AB ("Nosa Plugs" or "the Company") announced on 23 September 2026 that the Company has entered into an exclusive distribution agreement with the Moroccan pharmaceutical company Polymedic regarding sales of Nozoil Original and Nozoil Menthol on the Moroccan market. The launch is expected to take place following completion of the local registration process, which has been initiated and is estimated to take approximately two to four months. In connection with the launch, Polymedic is expected to place an initial order of approximately SEK 0.5m. Polymedic is responsible for local commercialization and distribution, with the products distributed through Polymedic's established relationships with national wholesalers, which in turn supply pharmacies and healthcare facilities across the country.
In summary, Analyst Group views the agreement with Polymedic as a positive development that broadens Nozoil's geographic presence to a further market in the MENA region through a capital efficient distributor model. The financial contribution is assessed to be limited in the near term and is expected mainly to strengthen revenue from 2027. The agreement is assessed to underline the commercial momentum Nozoil has shown since the acquisition of Pharmacure.
Read Analyst Group’s comment here (ENG & SV)
About Analyst Group: One of the Nordics’ leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on Nosa Plugs. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.